SHW
65
3
ADM
36
2
CAT
65
15
HBI
65
6
ABT
60
-2
ORLY
60
6
NOV
52
2
HON
45
-7
MPC
60
8
DOV
69
6
OKE
59
-5
HSY
58
11
GILD
49
2
MSI
50
-4
BEN
60
5
CMS
60
12
PBI
46
-2
FTI
86
7
URI
76
7
DG
20
2
SHW
65
3
ADM
36
2
CAT
65
15
HBI
65
6
ABT
60
-2
ORLY
60
6
NOV
52
2
HON
45
-7
MPC
60
8
DOV
69
6
OKE
59
-5
HSY
58
11
GILD
49
2
MSI
50
-4
BEN
60
5
CMS
60
12
PBI
46
-2
FTI
86
7
URI
76
7
DG
20
2
Financhill
Back

CRISPR Therapeutics AG Stock Predictions

Free presentation on how to trade options for overnight gains

Get the free overnight options training here.
Sell
50

CRSP
CRISPR Therapeutics AG

Last Price:
57.88
Seasonality Move:
-18.8%

7 Day Trial

ALL ACCESS PASS

$ 7

Groundbreaking AI Developed In Small Georgia Town Destroys Wall Street

See the remarkable discovery.

CRISPR Therapeutics AG Stock Forecast

  • Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 41% based on the past 7 years of stock performance.
  • CRISPR Therapeutics AG has risen higher in 3 of those 7 years over the subsequent 52-week period, corresponding to a historical accuracy of 42.86%
  • Is CRISPR Therapeutics AG Stock Undervalued?
    The current CRISPR Therapeutics AG [CRSP] share price is $57.57. The Score for CRSP is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
  • CRSP is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will CRISPR Therapeutics AG Stock Go Up Next Year?

  • Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 41% based on the past 7 years of stock performance.

CRISPR Therapeutics AG Stock Rating

Sell
50
CRISPR Therapeutics AG (CRSP) is a Sell

Is CRISPR Therapeutics AG overpriced?

  • CRISPR Therapeutics AG has risen higher in 3 of those 7 years over the subsequent 52-week period, corresponding to a historical accuracy of 42.86%

CRISPR Therapeutics AG Stock Price History

Is CRSP stock going to rise?

  • Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and CRSP is experiencing slight buying pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Switzerland
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
crisprtx.com

52-Week Data

52-Week High:
91.10
52-Week Low:
37.55

Prediction Charts

Market Cap:
4.89B
Price in USD:
57.57
Volume:
1.08M
Beta:
2.00

Technical Analysis

SMA50:
57.13
SMA100:
60.71
SMA200:
61.37
52-Wk Change:
3.84%

Stock Predictions

  • Is CRISPR Therapeutics AG stock public?
    Yes, CRISPR Therapeutics AG is a publicly traded company.
  • What is the CRISPR Therapeutics AG stock quote today?
    The CRISPR Therapeutics AG stock price is 57.57 USD today.
  • How to buy CRISPR Therapeutics AG stock online?
    You can buy CRISPR Therapeutics AG shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Jul-8 53.66 53.23 54.83 53.17
Jul-9 53.25 55.03 55.15 52.83
Jul-10 55.52 55.56 55.94 54.09
Jul-11 57.38 56.81 60.20 56.57
Jul-12 57.38 57.90 58.84 56.64
Jul-15 57.95 57.39 58.46 56.50
Jul-16 57.72 62.75 63.68 57.42
Jul-17 61.14 60.48 63.39 60.26
Jul-18 60.84 56.21 61.47 55.82
Jul-19 56.08 54.56 56.21 54.01
Jul-22 55.20 56.24 56.39 54.06
Jul-23 56.08 57.19 58.49 55.93
Jul-24 56.19 55.34 57.20 55.26
Jul-25 55.38 57.57 58.76 55.31

CRISPR Therapeutics AG Earnings

CRISPR Therapeutics AG Earnings Report: Per Share CRISPR Therapeutics AG Earnings Q1 Q2 Q3 and Q4 last year and next year.

CRISPR Therapeutics AG Forecast Revenue Growth

CRISPR Therapeutics AG Stock Analysis: Historical quarterly revenues per share for CRISPR Therapeutics AG and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.55 per share, a decrease next quarter of $0.01 per share, a decrease this year of $2.53 per share, and an increase next year of $1.20 per share.

* CRISPR Therapeutics AG stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.